AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17342880 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonactive group)
Number of subjects: 160
Study 15174232 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta 1a (Avonex) treatment, 30 mcg once a week
Number of subjects: 126
Study 10868001 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management of oral anticoagulation
Number of subjects: 2000
Study 10868001 — intervention group
Group type: COMPARATOR
Intervention: Conventional care by a general practitioner or specialist
Number of subjects: 2000
Study 9360409 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (intestinal lipase inhibitor)
Number of subjects: 53
Study 9360409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 1390306 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose continuous heparin
Number of subjects: 0
Study 1390306 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 4077235 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg/day) for 6 to 8 weeks
Number of subjects: 69
Study 4077235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 31393424 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine radiographs at 6 and 12 weeks)
Number of subjects: 326
Study 31393424 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced imaging (no routine radiographs at 6 and 12 weeks)
Number of subjects: 326
Study 31393424 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 326
Study 31393424 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced imaging
Number of subjects: 326
Study 29887423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-coronary sodium nitrite
Number of subjects: 80
Study 29887423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27179727 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 13887
Study 27179727 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily
Number of subjects: 13887
Study 24507164 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise (40%-60% of Heart Rate Reserve (HRR))
Number of subjects: 87
Study 24507164 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 87
Study 23126254 — intervention group
Group type: EXPERIMENTAL
Intervention: ISBT combined with interstitial hyperthermia (ISHT)
Number of subjects: 76
Study 23126254 — intervention group
Group type: COMPARATOR
Intervention: ISBT alone (control group)
Number of subjects: 76
Study 20556412 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Instruction (VI)
Number of subjects: 12
Study 20556412 — intervention group
Group type: COMPARATOR
Intervention: Verbal Instruction plus Augmented Feedback (VI + FB)
Number of subjects: 12
Study 17386184 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0
Study 15976952 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 1014
Study 15976952 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 1014
Study 16946363 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg/day
Number of subjects: 681
Study 16946363 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg/day
Number of subjects: 681
Study 16946363 — intervention group
Group type: EXPERIMENTAL
Intervention: paroxetine 20 mg/day
Number of subjects: 681
Study 16946363 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 681
Study 10322590 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of a semirigid ankle brace (Aircast Air-Stirrup)
Number of subjects: 11
Study 10322590 — intervention group
Group type: COMPARATOR
Intervention: Nonbraced condition
Number of subjects: 11
Study 8647140 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg modified release formulation once daily)
Number of subjects: 244
Study 1825323 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac 200 mg b.i.d.
Number of subjects: 48
Study 1825323 — intervention group
Group type: COMPARATOR
Intervention: naproxen 500 mg b.i.d.
Number of subjects: 48
Study 6836825 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of gentamicin two hours preoperatively
Number of subjects: 0
Study 6836825 — intervention group
Group type: EXPERIMENTAL
Intervention: Three schedules of gentamicin administration
Number of subjects: 0
Study 6836825 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 0
Study 30316534 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 U vitamin D3 pearl weekly for 8 weeks)
Number of subjects: 78
Study 30316534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 30016983 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaozhen formula and basic treatment
Number of subjects: 266
Study 30016983 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment only
Number of subjects: 266
Study 26341604 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD after TV-ICD extraction for system-related infection
Number of subjects: 866
Study 26341604 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD after TV-ICD extraction for reasons other than system-related infection
Number of subjects: 866
Study 26341604 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD de novo implantations
Number of subjects: 866
Study 25438272 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (R group; n = 22)
Number of subjects: 44
Study 25438272 — intervention group
Group type: COMPARATOR
Intervention: Saline (S group; n = 22)
Number of subjects: 44
Study 22812577 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy intake (4 servings of reduced-fat dairy per day)
Number of subjects: 0
Study 22812577 — intervention group
Group type: COMPARATOR
Intervention: Low dairy intake (1 serving of reduced-fat dairy per day)
Number of subjects: 0
Study 21375022 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine plus mental-regulating acupoints treatment group
Number of subjects: 20
Study 21375022 — intervention group
Group type: COMPARATOR
Intervention: Control group (TENS, acupuncture, TDP irradiation, pellet-pressure)
Number of subjects: 20
Study 21375022 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment sessions
Number of subjects: 20
Study 17634487 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term androgen-deprivation therapy (LTAD) plus radiotherapy (RT)
Number of subjects: 612
Study 17634487 — intervention group
Group type: COMPARATOR
Intervention: Short-term androgen-deprivation therapy (STAD) plus radiotherapy (RT)
Number of subjects: 612
Study 16287386 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-therapy emotional arousal
Number of subjects: 32
Study 16287386 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid- and late treatment perceptual processing
Number of subjects: 32
Study 16287386 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional arousal and perceptual processing during mid-therapy
Number of subjects: 32
Study 11929394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 1 mg
Number of subjects: 28
Study 11929394 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 1 mg and 2 mg
Number of subjects: 28
Study 11929394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10517273 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface electromyogram (SEMG) technique (189 MUs)
Number of subjects: 16
Study 10517273 — intervention group
Group type: COMPARATOR
Intervention: Cross-correlation of MU discharge (498 MU pairs)
Number of subjects: 16
Study 7545763 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily recombinant human growth hormone (rhGH), 0.15 mg/kg IM
Number of subjects: 18
Study 7545763 — intervention group
Group type: COMPARATOR
Intervention: Not receiving rhGH (Control group)
Number of subjects: 18
Study 31394380 — intervention group
Group type: EXPERIMENTAL
Intervention: BIONEX (EMG-biofeedback guided exercises)
Number of subjects: 49
Study 31394380 — intervention group
Group type: COMPARATOR
Intervention: NEX (same exercises without EMG-biofeedback)
Number of subjects: 49
Study 31394380 — intervention group
Group type: EXPERIMENTAL
Intervention: BIONEX
Number of subjects: 49
Study 31394380 — intervention group
Group type: COMPARATOR
Intervention: NEX
Number of subjects: 49
Study 28117049 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 5 mg
Number of subjects: 1199
Study 28117049 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 10 mg (DayLyte)
Number of subjects: 1199
Study 28117049 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 10 mg (FlashLyte)
Number of subjects: 1199
Study 28117049 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 20 mg (FlashLyte)
Number of subjects: 1199
Study 28117049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study 26690825 — intervention group
Group type: EXPERIMENTAL
Intervention: High visceral fat to subcutaneous fat ratio (VFA/SFA)
Number of subjects: 42
Study 26690825 — intervention group
Group type: COMPARATOR
Intervention: Low visceral fat to subcutaneous fat ratio (VFA/SFA)
Number of subjects: 42
Study 26690825 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic score combining VFA/SFA, LDH, and liver metastasis
Number of subjects: 42
Study 23668834 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (distribution of educational materials, online course, three on-site workshops)
Number of subjects: 3018
Study 23668834 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline information collected retrospectively)
Number of subjects: 3018
Study 21413974 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose BoNT‐B (1500 MU)
Number of subjects: 27
Study 21413974 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose BoNT‐B (3000 MU)
Number of subjects: 27
Study 21413974 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose BoNT‐B (5000 MU)
Number of subjects: 27
Study 21413974 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BoNT‐B)
Number of subjects: 27
Study 18499270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (maintenance therapy)
Number of subjects: 21
Study 15766814 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI in women
Number of subjects: 763
Study 15766814 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI in men
Number of subjects: 763
Study 15766814 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender as a predictor
Number of subjects: 763
Study 12032514 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 36
Study 12032514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no growth hormone treatment)
Number of subjects: 36
Study 10232715 — intervention group
Group type: COMPARATOR
Intervention: 75 mg lidocaine 5% intrathecally (group A)
Number of subjects: 40
Study 10232715 — intervention group
Group type: COMPARATOR
Intervention: 0.15 mg x kg(‐1) meperidine (group B) co-administered with lidocaine
Number of subjects: 40
Study 10232715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg x kg(‐1) meperidine (group C) co-administered with lidocaine
Number of subjects: 40
Study 8730115 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus prednisone
Number of subjects: 24
Study 8730115 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 24
Study 1862156 — intervention group
Group type: EXPERIMENTAL
Intervention: epictor (EGF)
Number of subjects: 0
Study 1862156 — intervention group
Group type: EXPERIMENTAL
Intervention: platelet derived growth factor (PDGF)
Number of subjects: 0
Study 6676478 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate 0.04 mg kg‐1 BW iv
Number of subjects: 10
Study 6676478 — intervention group
Group type: COMPARATOR
Intervention: Naloxone 3 micrograms kg‐1 BW iv
Number of subjects: 10
Study 28261848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine (30 mg) on demand (Group 1)
Number of subjects: 105
Study 28261848 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activities (Group 2)
Number of subjects: 105
Study 28261848 — intervention group
Group type: COMPARATOR
Intervention: Minimal physical activity (Group 3 - sham)
Number of subjects: 105
Study 26408420 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS + DIMST
Number of subjects: 0
Study 26408420 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS + sham-DIMST
Number of subjects: 0
Study 26408420 — intervention group
Group type: EXPERIMENTAL
Intervention: sham-rTMS + DIMST
Number of subjects: 0
Study 26408420 — intervention group
Group type: COMPARATOR
Intervention: sham-rTMS + sham-DIMST
Number of subjects: 0
Study 26408420 — intervention group
Group type: EXPERIMENTAL
Intervention: All active groups
Number of subjects: 0
Study 26408420 — intervention group
Group type: EXPERIMENTAL
Intervention: All peripheral parameters
Number of subjects: 0
Study 23907370 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus cetuximab
Number of subjects: 141
Study 23907370 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 141
Study 22127555 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam administration
Number of subjects: 0
Study 22127555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20669630 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug chemotherapy regimens
Number of subjects: 0
Study 20669630 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 18715415 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate oxytocin administration
Number of subjects: 412
Study 18715415 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin withheld for up to 8 hours (conservative group)
Number of subjects: 412
Study 16060280 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference currents
Number of subjects: 0
Study 12202899 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and paclitaxel (AT combination)
Number of subjects: 0
Study 12202899 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracyl, doxorubicin and cyclophosphamid (FAC)
Number of subjects: 0
Study 10980848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 0
Study 7726087 — intervention group
Group type: COMPARATOR
Intervention: Cumulative standard dose (0.1 mmol/kg)
Number of subjects: 45
Study 7726087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative triple dose (0.3 mmol/kg)
Number of subjects: 45
Study 7726087 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed imaging after injection of standard contrast dose
Number of subjects: 45
Study 7726087 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed imaging after injection of higher contrast dose
Number of subjects: 45
Study 2343736 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural injection of 20 ml of 0.375% bupivacaine mixed with 10 ml contrast medium in the supine position (11 patients)
Number of subjects: 21
Study 2343736 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural injection of 20 ml of 0.375% bupivacaine mixed with 10 ml contrast medium in the lateral position (10 patients)
Number of subjects: 21
Study 2343736 — intervention group
Group type: COMPARATOR
Intervention: Interpleural injection of 20 ml of 0.375% bupivacaine mixed with 10 ml contrast medium
Number of subjects: 21
Study 7386530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose administration
Number of subjects: 0
Study 7386530 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline solution administration
Number of subjects: 0
Study 31468402 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary taurine supplementation (3 g of taurine)
Number of subjects: 31
Study 31468402 — intervention group
Group type: COMPARATOR
Intervention: Control group (scorched rice water without taurine)
Number of subjects: 31
Study 31468402 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary taurine supplementation
Number of subjects: 31
Study 28292532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy (200mg Venofer® diluted in 100ml saline)
Number of subjects: 0
Study 28292532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100ml saline)
Number of subjects: 0
Study 25774878 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer self-administration of the CRAFFT screening protocol
Number of subjects: 136
Study 25774878 — intervention group
Group type: COMPARATOR
Intervention: Clinician-administration of the CRAFFT screening protocol
Number of subjects: 136
Study 25343657 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically assisted detoxification
Number of subjects: 262
Study 25343657 — intervention group
Group type: COMPARATOR
Intervention: No medically assisted detoxification
Number of subjects: 262
Study 23001955 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 0
Study 23001955 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol decanoate depot
Number of subjects: 0
Study 19508532 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy (SH)
Number of subjects: 60
Study 19508532 — intervention group
Group type: COMPARATOR
Intervention: Rubber band ligation (RBL)
Number of subjects: 60
Study 17870260 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone 1.25mg/day
Number of subjects: 308
Study 17870260 — intervention group
Group type: COMPARATOR
Intervention: raloxifene 60 mg/day
Number of subjects: 308
Study 15927965 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitachycardia pacing for fast ventricular tachycardia (FVT)
Number of subjects: 582
Study 15927965 — intervention group
Group type: COMPARATOR
Intervention: Shock for fast ventricular tachycardia (FVT)
Number of subjects: 582
Study 12437455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tazarotene cream
Number of subjects: 563
Study 12437455 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 563
Study 10481500 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine effect on T lymphocytes in patients with seasonal allergic rhinitis
Number of subjects: 240
Study 10481500 — intervention group
Group type: COMPARATOR
Intervention: Allergic skin tests, serum level of IgE, Multitest CMI, percentage of lymphocytes T (CD3), percentage of lymphocytes T helper (CD4), percentage of lymphocytes T cytotoxic (CD8)
Number of subjects: 240
Study 8623802 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 40
Study 8623802 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 40
Study 1946889 — intervention group
Group type: EXPERIMENTAL
Intervention: Active behavioral task (32 subjects)
Number of subjects: 96
Study 1946889 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (9 subjects)
Number of subjects: 96
Study 1946889 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 subjects)
Number of subjects: 96
Study 1946889 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (15 subjects)
Number of subjects: 96
Study 7116662 — intervention group
Group type: EXPERIMENTAL
Intervention: Active regimen (hydrochlorothiazide‐triamterene with or without methyldopa)
Number of subjects: 0
Study 7116662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29147968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 35 days
Number of subjects: 35
Study 29147968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 5 days
Number of subjects: 35
Study 29147968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 7 days
Number of subjects: 35
Study 29147968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 14 days
Number of subjects: 35
Study 29147968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 1 day
Number of subjects: 35
Study 29147968 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged fasting
Number of subjects: 35
Study 29147968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 35
Study 27659392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia education program delivered to intervention group (IG)
Number of subjects: 745
Study 27659392 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed group (control)
Number of subjects: 745
Study 24879975 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropes used in patients with SBP <100 mm Hg (53.3% of 165 patients)
Number of subjects: 427
Study 24879975 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropes used in patients with SBP ≥100 mm Hg (40.5% of 262 patients)
Number of subjects: 427
Study 24879975 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropes used in patients with cardiac index ≥1.8 L min(‐1) m(‐2) (n = 114)
Number of subjects: 427
Study 24879975 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropes used in patients with cardiac index <1.8 L min(‐1) m(‐2) (n = 82)
Number of subjects: 427
Study 24879975 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropes used in ischemic patients (n = 215)
Number of subjects: 427
Study 24879975 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropes used in nonischemic patients (n = 216)
Number of subjects: 427
Study 24879975 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotropes used in all subgroups
Number of subjects: 427
Study 23859257 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 3 months
Number of subjects: 100
Study 23859257 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 6 months
Number of subjects: 100
Study 23859257 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 100
Study 23859257 — intervention group
Group type: COMPARATOR
Intervention: Control group (obese nonapneic matched controls)
Number of subjects: 100
Study 20579357 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle program (diet, increased physical activity, and behavioral modification) aiming for 5%-10% weight loss over six months.
Number of subjects: 0